Linezolid 600mgTablet
Antibiotics

Linezolid 600mg

Linezolid

First-in-class oxazolidinone antibiotic that inhibits bacterial protein synthesis at a unique ribosomal step (50S subunit formation), with no cross-resistance to other antibiotic classes, making it a critical reserve agent for MRSA, vancomycin-resistant Enterococcus, and multidrug-resistant tuberculosis. Its oral bioavailability of approximately 100% enables seamless IV-to-oral step-down therapy with equivalent serum levels, a key clinical advantage in MDR infection management. Cipla and Glenmark supply 600mg tablets exported to infectious disease and MDR-TB programmes worldwide.

Strengths

600mg

Packing

10 tablets/strip

Origin

India (WHO-GMP)

MOQ

100 units

Export Price

On Request

Availability

In Stock

Quotation with pricing, availability, and shipping timeline sent within 24 hours.

Product Specifications

Composition
Linezolid 600mg
Dosage Form
Tablet
Available Strengths
600mg
Packing
10 tablets/strip
Route of Administration
Oral, with or without food
Dosage
600mg every 12 hours for 10-28 days depending on infection type
Indications
MRSA infections, vancomycin-resistant Enterococcus (VRE), nosocomial and community-acquired pneumonia, complicated skin infections
Country of Origin
India (WHO-GMP Certified)
Storage
Store at 25°C, protected from light and moisture
Shelf Life
24 months
Side Effects
Diarrhea, nausea, headache, vomiting, anemia, thrombocytopenia, lactic acidosis
Precautions
Monitor blood counts weekly; risk of serotonin syndrome with serotonergic agents; avoid tyramine-rich foods; peripheral and optic neuropathy with prolonged use (>28 days)

Disclaimer: This information is intended for healthcare professionals and international pharmaceutical buyers only. Product availability, registration status, and approved indications may vary by country. All products are supplied with Certificate of Analysis (CoA), commercial invoice, and packing list. Rx products require valid prescription in the destination country.

Related Products

Azithromycin 500mgTablet

Azithromycin 500mg

Azithromycin

Azalide subclass macrolide antibiotic that achieves exceptionally high and sustained intracellular tissue concentrations — up to 100-fold higher than plasma levels — enabling short 3-day or 5-day treatment courses for respiratory, skin, and sexually transmitted bacterial infections. Its anti-inflammatory properties beyond direct bacteriostasis provide additional clinical benefit in community-acquired pneumonia. Cipla and Alkem Labs manufacture 250mg and 500mg tablets exported globally as a staple of primary care antibiotic formularies.

250mg / 500mg
Amoxicillin 500mgCapsule

Amoxicillin 500mg

Amoxicillin Trihydrate

Aminopenicillin with extended gram-positive and gram-negative bactericidal activity, offering superior oral bioavailability (~90%) compared to ampicillin and the convenience of twice- or thrice-daily dosing for common community infections of the respiratory tract, urinary tract, skin, and ear. It is also a key component of H. pylori triple-eradication therapy and is a WHO Essential Medicine available in both capsule and dispersible tablet forms. Cipla and GSK manufacture 250mg and 500mg capsules exported to primary care markets globally.

250mg / 500mg
Augmentin 625mgTablet

Augmentin 625mg

Amoxicillin + Clavulanate

Fixed-dose combination of amoxicillin with clavulanic acid, a potent beta-lactamase inhibitor that protects amoxicillin from enzymatic degradation and restores its activity against beta-lactamase-producing strains of Staphylococcus, Haemophilus, Moraxella, and Klebsiella commonly encountered in community and hospital settings. Widely prescribed for sinusitis, otitis media, lower respiratory infections, UTIs, animal bites, and dental abscesses resistant to amoxicillin alone. GSK and Cipla supply 625mg and 1g tablets exported as a primary care antibiotic staple worldwide.

625mg / 1g

Need bulk pricing for Linezolid 600mg?

Send us your quantity requirements and destination country for a custom quotation.

Get Bulk Quote